Medidata Solutions
announced that specialty contract research organization (CRO) QCTR Ltd. has selected Medidata CTMS, including its investigator site payment module, to manage the operations of all their clinical studies.
Scotland-based QCTR was founded in 2006 to fill an ndustry need for CRO expertise in central nervous system (CNS) clinical research. As their study pipeline grew, QCTR realized that a commercial trial management solution was necessary to efficiently do more with existing resource.
“Compared to other available systems, Medidata’s SaaS-based CTMS solution offered much greater value in terms of richness of features, speed of set-up, flexibility, ease-of-use and global accessibility—without requiring extensive up-front investment,” said Susan McGoldrick, Managing Director, QCTR. “It’s evident that Medidata CTMS was developed with CRO-specific needs in mind. We’re especially excited about the opportunities to more proactively manage the performance of investigator sites and streamline how we pay them—key aspects in our strategy to maintain our sites’ high satisfaction and patient recruitment excellence as we scale our business.”
QCTR anticipates that Medidata CTMS will greatly reduce the time and effort needed to track key milestones and operational metrics across their clinical studies and sites—both from the perspective of data entry as well as timely access to information and reports. As a result, study managers and monitors should be able to maintain a tight handle on issues despite increased study volumes and quickly follow up with sites.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.